[{"id":"cd832ab8-7587-4c71-9c65-7ea5f604b0d0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04323657","created_at":"2021-01-18T20:56:50.005Z","updated_at":"2024-07-02T16:35:53.161Z","phase":"Phase 1/2","brief_title":"TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT04323657","lead_sponsor":"TCR2 Therapeutics","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TC-110"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 03/27/2020","start_date":" 03/27/2020","primary_txt":" Primary completion: 02/24/2023","primary_completion_date":" 02/24/2023","study_txt":" Completion: 02/24/2023","study_completion_date":" 02/24/2023","last_update_posted":"2023-03-16"}]